The role of IL-17A in GPP disease is supported in part by case reports and small clinical trials from Japan detailing the clinical improvement and resolution of systemic symptoms in some patients with GPP treated with selective IL-17A (secukinumab and ixekizumab) and IL-17R (brodalumab) antagonists (76–80). Here, IL17RA is linked to psoriasis 14, pustular.